Strategically targeting MYC in cancer
Open Access
- 29 March 2016
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
Abstract
MYC is a major driver of cancer cell growth and mediates a transcriptional program spanning cell growth, the cell cycle, metabolism, and cell survival. Many efforts have been made to deliberately target MYC for cancer therapy. A variety of compounds have been generated to inhibit MYC function or stability, either directly or indirectly. The most direct inhibitors target the interaction between MYC and MAX, which is required for DNA binding. Unfortunately, these compounds do not have the desired pharmacokinetics and pharmacodynamics for in vivo application. Recent studies report the indirect inhibition of MYC through the development of two compounds, JQ1 and THZ1, which target factors involved in unique stages of transcription. These compounds appear to have significant therapeutic value for cancers with high levels of MYC, although some effects are MYC-independent. These approaches serve as a foundation for developing novel compounds to pharmacologically target MYC-driven cancers.Keywords
This publication has 59 references indexed in Scilit:
- c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem CellsCell, 2012
- Transcriptional Amplification in Tumor Cells with Elevated c-MycCell, 2012
- Reflecting on 25 years with MYCNature Reviews Cancer, 2008
- The c-Myc target gene networkSeminars in Cancer Biology, 2006
- c-Myc regulates mammalian body size by controlling cell number but not cell sizeNature, 2001
- Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activationGenes & Development, 2001
- The Essential Cofactor TRRAP Recruits the Histone Acetyltransferase hGCN5 to c-MycMolecular and Cellular Biology, 2000
- The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F OncoproteinsCell, 1998
- Sequence-Specific DNA Binding by the c-Myc ProteinScience, 1990
- Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells.1987